Dipharma SA confirms the recognition as one of the best companies to work for in Switzerland Chiasso, Switzerland, November 6th, 2023 | Dipharma SA, a pharmaceutical company specialized in high quality and improved medicines for rare diseases, h...

Chiasso, Switzerland and Reading, England, October 4th, 2023 – Dipharma SA (“Dipharma”) and LogixX Pharma (“LogixX”) are delighted to announce the official launch of Sapropterin Dihydrochloride (“Sapropterin”) in the United Kingdom. Sapropterin Di...

Visit us at our booth N11 at the SSIEM  from 29.08.-01.09.2023  in Jerusalem, Israel, we are looking forward to meet you there.

SAPROPTERIN DIPHARMA IS NOW AVAILABLE IN EUROPE AND SWITZERLAND Chiasso, Switzerland, July 3rd, 2023 – – Dipharma SA (“Dipharma”) today announced that its product Sapropterin Dipharma is now available in main European Countries and in Switzerland....

Chiasso, Switzerland and Reading, England, June 27, 2023 – Dipharma SA (“Dipharma”) and LogixX Pharma (“LogixX”) are pleased to announce that the Medicines and Healthcare Products Regulatory Agency (“MHRA”) has granted Marketing Authorization for ...

Princeton, NJ and Chiasso, Switzerland, May 31st, 2023 | Analog Pharma (member of Duchesnay Pharmaceutical Group, hereafter “Analog”) and Dipharma S.A. (“Dipharma”) is pleased to announce that their 20 mg nitisinone abbreviated new drug applicatio...

Chiasso, September 15th, 2022 | Dipharma SA, a specialty pharmaceutical company specialized in high quality and improved medicines for rare diseases, has been recently recognized as one of the best places to work for in Switzerland. During the ass...

Visit us at our booth at the APS from 19.10.-21.10.2022 in Kassel, Germany, we are looking forward to meet you there.

Rosemont, PA and Chiasso, Switzerland, June 21st, 2022 – Analog Pharma (“Analog”) and Dipharma S.A. (“Dipharma”) today announced that their nitisinone abbreviated new drug application (ANDA) has received final approval from the U.S. Food and Drug ...